283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)

283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)

Bibliographic Details
Main Authors: Alexander Stevenson, Jianjun Gao, Pavlos Msaouel, Nizar Tannir, Mehmet Altan, Shi-Ming Tu, Michael Chisamore, Matthew Campbell, George Blumenschein, Xiuning Le, Frank Mott, Amishi Shah, Jordi Rodon, Imke Mulder
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items